Pell Bio-Med Technology Co., Ltd.
Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications. Its commercial products include good tissue practice laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative medicine, and CIK and DC-CIK against cancers. The company also develops medicines for various types of cancers… Read more
Pell Bio-Med Technology Co., Ltd. (6949) - Total Assets
Latest total assets as of September 2025: NT$1.62 Billion TWD
Based on the latest financial reports, Pell Bio-Med Technology Co., Ltd. (6949) holds total assets worth NT$1.62 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pell Bio-Med Technology Co., Ltd. - Total Assets Trend (2021–2024)
This chart illustrates how Pell Bio-Med Technology Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Pell Bio-Med Technology Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Pell Bio-Med Technology Co., Ltd.'s total assets of NT$1.62 Billion consist of 66.4% current assets and 33.7% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 24.5% |
| Accounts Receivable | NT$4.31 Million | 0.3% |
| Inventory | NT$6.18 Million | 0.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$1.89 Million | 0.1% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Pell Bio-Med Technology Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pell Bio-Med Technology Co., Ltd.'s current assets represent 66.4% of total assets in 2024, an increase from 33.5% in 2021.
- Cash Position: Cash and equivalents constituted 24.5% of total assets in 2024, down from 29.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 0.4% of total assets.
Pell Bio-Med Technology Co., Ltd. Competitors by Total Assets
Key competitors of Pell Bio-Med Technology Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Pell Bio-Med Technology Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Pell Bio-Med Technology Co., Ltd. generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Pell Bio-Med Technology Co., Ltd. is currently not profitable relative to its asset base.
Pell Bio-Med Technology Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.49 | 12.01 | 12.67 |
| Quick Ratio | 3.47 | 11.95 | 12.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$671.83 Million | NT$ 1.12 Billion | NT$ 668.15 Million |
Pell Bio-Med Technology Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between Pell Bio-Med Technology Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 23.45 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | 23.0% |
| Total Assets | NT$1.74 Billion |
| Market Capitalization | $507.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pell Bio-Med Technology Co., Ltd.'s assets below their book value (0.29 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Pell Bio-Med Technology Co., Ltd.'s assets grew by 23.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Pell Bio-Med Technology Co., Ltd. (2021–2024)
The table below shows the annual total assets of Pell Bio-Med Technology Co., Ltd. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.74 Billion | +23.04% |
| 2023-12-31 | NT$1.42 Billion | +35.79% |
| 2022-12-31 | NT$1.04 Billion | +165.15% |
| 2021-12-31 | NT$393.89 Million | -- |